LENGTH OF HOSPITAL STAYS OF PATIENTS OPERATED DUE TO GLIOMA TUMOURS IN NEUROSURGERY CLINICS AND INTENSIVE CARE UNITS

Yıl 2021, Cilt: 8 Sayı: 2, 81 - 84, 30.06.2021

Irmak Özyiğit , Fatih Erkan Akay , Elif Cengiz , Janset Özdemir , Pınar Tuncer , Eylül Şenödeyici , Sarper Kızılkaya , Ahmet Tolgay Akıncı

Öz

Aims: To evaluate the relationship between the length of hospital stay and age, gender, and disease characteristics among glioma patients who went under surgery in Trakya University School of Medicine. Methods: The data of 51 glioma patients over 18 years of age, who have been followed up during 2019-2020 in Trakya University School of Medicine, Department of Neurosurgery were analyzed. Patients' data comprised of sex, age, tumour location, grades of the tu- mours, the presence of isocitrate dehydrogenase mutation, whether the patients were hospitalized in the intensive care unit or the neurosurgery clinic, duration of hospitalization, and whether radiotherapy and chemotherapy was received. Length of hospital stay was evaluated separately as intensive care unit and the neurosurgery clinic. Results: Out of 51 patients diagnosed with glioma, 18 (35.3%) were female, and 33 (64.7%) were male. The length of neurosurgery clinic and intensive care unit stays were not associated with radiotherapy and chemotherapy approaches. There was a statistically significant difference between the male and female patients in terms of the number of days stayed in the neurosurgery clinic. Conclusion: In conclusion, gender affected the length of neurosurgery clinic stays with a longer duration for female patients in our clinic. A waste number of parameters, including social ones, affect hospital stays. To reveal predictors of postoperative hospitalization thoroughly and overcome the study’s limitations, further prospective studies with larger sample sizes are needed.

Anahtar Kelimeler

Glioma, hospitalization, isocitrate dehydrogenase, retrospective study

Kaynakça

• 1. Ostrom QT, Bauchet L, Davis FG et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 2014;16(7):896-913.
• 2. Mesfin FB, Al-Dhahir MA. Gliomas. StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
• 3. Schneider T, Mawrin C, Scherlach C et al. Gliomas in adults. Dtsch Arztebl Int 2010;107(45):799-807.
• 4. Davis ME. Epidemiology and overview of gliomas. Semin Oncol Nurs 2018;34(5):420-9.
• 5. Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 2018;44(2):139-50.
• 6. Ostrom QT, Cote DJ, Ascha M et al. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 2018;4(9):1254- 62.
• 7. Batash R, Asna N, Schaffer P et al. Glioblastoma multiforme, diagnosis and treat- ment; recent literature review. Curr Med Chem 2017;24(27):3002-9.
• 8. Vega RA, Traylor JI, Patel R et al. Combined surgical resection and laser intersti- tial thermal therapy for glioblastoma: technical note. J Neurol Surg A Cent Eur Neurosurg 2020;81(4):348-54.
• 9. Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther 2015;152:63-82.
• 10. Malmström A, Grønberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13(9):916-26.
• 11. Wasilewski A, Serventi J, Kamalyan L et al. Acute care in glioblastoma: the burden and the consequences. Neurooncol Pract 2017;4(4):248-54.
• 12. Muhlestein WE, Akagi DS, Davies JM et al. Predicting inpatient length of stay after brain tumor surgery: developing machine learning ensembles to improve predictive performance. Neurosurgery 2019;85(3):384-93.
• 13. Dasenbrock HH, Liu KX, Devine CA et al. Length of hospital stay after crani- otomy for tumor: a National Surgical Quality Improvement Program analysis. Neurosurg Focus 2015;39(6):E12.
• 14. Arvold ND, Wang Y, Zigler C et al. Hospitalisation burden and survival among older glioblastoma patients. Neuro Oncol 2014;16(11):1530-40.
• 15. Rahman R, Catalano PJ, Reardon DA et al. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neu- rooncol 2015;124(1):137-46.
• 16. Ben Nasr S, Haddaoui A, Bach Hamba S et al. Glioblastoma in Tunisia: a retro- spective study about 41 cases. Tunis Med 2015;93(10):598-601.
• 17. Verlut C, Mouillet G, Magnin E et al. Age, neurological status MRC scale, and postoperative morbidity are prognostic factors in patients with glioblastoma treated by chemoradiotherapy. Clin Med Insights Oncol 2016;10:77-82.
• 18. Jan BM, Sarmast AH, Bhat AR et al. Profile of high grade gliomas - a single center experience. Gulf J Oncolog 2018;1(26):27-32.
• 19. Moroney C, Perry JR, Tsang DS et al. Hospitalizations in elderly glioblastoma patients. Ann Palliat Med 2017;6(Suppl 2):161-9.